Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's Cagrisema?
Cagrisema is a recombinant peptide and synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program in Type...